Zanganeh Mahkam 4
4 · Summit Therapeutics Inc. · Filed May 1, 2025
Insider Transaction Report
Form 4
Zanganeh Mahkam
DirectorCo-Chief Executive Officer10% Owner
Transactions
- Award
Stock Option (right to buy)
2025-04-29+1,040,000→ 1,040,000 totalExercise: $1.06Exp: 2032-06-28→ Common Stock (1,040,000 underlying) - Award
Stock Option (right to buy)
2025-04-29+9,590,558→ 9,590,558 totalExercise: $1.68Exp: 2033-10-13→ Common Stock (9,590,558 underlying) - Award
Stock Option (right to buy)
2025-04-29+400,000→ 400,000 totalExercise: $1.29Exp: 2032-09-09→ Common Stock (400,000 underlying)
Footnotes (2)
- [F1]Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025.
- [F2]Not applicable.